With these examples in mind, the results recently published from a phase 3 trial of vorasidenib in IDH-mutant low-grade glioma (122) and from a phase 1 trial of vorasidenib and the IDH1 mutation inhibitor ivosidenib, also in IDH1-mutant low-grade glioma (210) pointed to potential treatment improvements for low-grade glioma. This evidence concerns the gene IDH1 and glioma.